FAQ, made simple

Tirzepatide is the first dual GIP / GLP-1 receptor agonist.

In the SURMOUNT-1 trial, patients on the 15 mg dose lost an average of 22.5% of body weight over 72 weeks.

Longegra physicians almost always start patients at 2.5 mg once weekly for the first 4 weeks.

Tirzepatide is a once-weekly subcutaneous injection in the abdomen, thigh or upper arm using an ultra-fine 30–31G insulin syringe.

The most common side effects are GI-related: nausea (~22% of patients), diarrhoea, constipation, reflux and reduced appetite — usually mild, dose-dependent and easing within 1–2 weeks of each titration step.

Head-to-head trials (SURMOUNT-1 vs STEP-1) suggest Tirzepatide produces ~50% more weight loss than Semaglutide at maximum dose (≈22% vs ≈15%) with a similar side-effect profile.

Some weight regain is biologically expected — the STEP-4 and SURMOUNT-4 trials showed roughly two-thirds of lost weight returns within a year of discontinuation if no maintenance plan is in place.

Yes — Tirzepatide (sold internationally as Mounjaro) was originally approved for Type 2 diabetes and has very strong HbA1c and fasting-glucose data.

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), multiple endocrine neoplasia type 2 (MEN-2), severe gastroparesis, active pancreatitis, or pregnancy / breastfeeding.

Any rapid weight loss — Tirzepatide or otherwise — risks ~25–40% of the lost mass being lean tissue.

Obesity is now classified as a chronic relapsing disease, so most international guidelines (and Longegra physicians) treat Tirzepatide as a long-term therapy — like a statin or anti-hypertensive — rather than a 90-day course.

Yes.

Moderate alcohol is generally compatible with Tirzepatide, but many patients report alcohol tastes 'flat' or causes worse-than-expected hangovers because of slowed gastric emptying.

Emerging evidence (and clinical experience at Longegra) suggests yes.

Pricing depends on dose and supplier batch.

Yes.

Yes — Tirzepatide is a prescription-only therapy.

After your intake form, you are matched to a Longegra physician trained in metabolic and peptide medicine.

Yes.

Every vial we ship is sourced from licensed compounding pharmacies and finished-product manufacturers with documented Certificates of Analysis (CoA), batch records and third-party HPLC purity testing.

Tirzepatide is shipped overnight in temperature-validated cold-chain packaging (2–8 °C) with phase-change refrigerants and a calibrated temperature logger inside the box.

Once your physician approves your Tirzepatide prescription and payment is confirmed, your order is dispatched the next working day from our cold-chain hub.

Every package contains a calibrated temperature logger you can read on arrival.

Reconstituted Tirzepatide is stored in a domestic refrigerator at 2–8 °C, away from the freezer wall and out of direct light.